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SIGNIFICANCE
Eccrine porocarcinoma is a skin cancer arising from skin 
sweat glands. Not much is known about the behaviour 
of eccrine porocarcinoma or its rate in populations. This 
study analysed data from the Finnish Cancer Registry, to 
determine the incidence of patients with eccrine porocarci-
noma in Finland during 2007 to 2017. There were a total of 
69 patients during this period, of whom half were women 
and half were men. The patients had a mean age of over 
75 years. The incidence was 0.045 per 100,000 person-
years. One patient died of eccrine porocarcinoma. Eccrine 
porocarcinoma is very rare skin cancer and the mortality is 
lower than previously reported.
Malignant eccrine porocarcinoma is a rare skin adnexal 
cancer arising from the sweat glands. Little is known 
about the epidemiology and incidence of eccrine poro-
carcinoma. This registry-based study examined the 
epidemiology and incidence data for eccrine porocar-
cinoma from the Finnish Cancer Registry. The study 
included all persons diagnosed with eccrine porocar-
cinoma in 2007 to 2017. There were 69 cases in the 
study period; 34 (49%) male and 35 (51%) female 
patients. Mean age at diagnosis was 75.5 years. Inci-
dence for men was 0.06 per 100,000 person-years and 
for women 0.04 per 100,000 person-years adjusted 
for age according to the World Standard Population. 
Incidence increased with age. There was one eccrine 
porocarcinoma-specific death among the 69 patients. 
The incidence of eccrine porocarcinoma in Finland is 
therefore low. The mean age at time of diagnosis and 
the location of eccrine porocarcinoma are consistent 
with previous reports. The survival of patients with ec-
crine porocarcinoma is high.
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Malignant eccrine porocarcinoma (EPC) is a rare skin cancer, which arises from the intraepidermal 
part of the sweat gland, the acrosyringium. EPC occurs 
predominantly in elderly people;The reported mean age 
at diagnosis varied from 62 to 76 years (1–6). The first 
reported cases of EPC were described in 1963by Pinkus 
& Mehregan, who called it “epidermotropic eccrine car-
cinoma” due to its morphological similarities to benign 
poroma and to Paget’s disease (7). Mishima & Moriko 
later coined the term “eccrine porocarcinoma”, after 
studying oncogenic differentiation in sweat glands (8).
Published findings regarding the sex-specific inci-
dence of EPC are contradictory. Systematic reviews of 
453 cases and 206 cases show contradicting reports of 
the incidence between sexes (4, 9). A recent study of 
the data from the National Cancer Database in the USA 
showed slight male overrepresentation; 51.2% vs 48.8% 
(10). These systemic reviews and the National Cancer 
Database found that the most common locations of EPC 
are the head and neck area and lower limbs (4, 9, 10). 
EPC commonly presents as a firm nodule or a plaque 
of violet or erythematous colour. EPC can also present 
as a skin-coloured plaque with oozing. Ulceration of the 
lesion may also occur (1, 9, 11). The median size of the 
tumour at diagnosis is reported to be 2 cm (2). The mean 
time between the appearance of the tumour and diagnosis 
has been reported as 5–9 years (2, 9), but may vary from 
4 days to 60 years (1, 2, 5, 9). 
EPC is difficult to diagnose; cutaneous squamous cell 
carcinoma is the most common misdiagnosis and, less 
frequently, other cutaneous cancers (1–3). It has been 
suggested that EPC arises from its benign counterpart, 
eccrine poroma. Robson et al. (2) observed that 18% of 
the EPC cases developed from a background of eccrine 
poroma, and Riera-Leal et al. (5) observed that 12% de-
veloped from this background. Shaw et al. (1) concluded 
that all 27 EPC cases in their study developed alongside 
a benign eccrine poroma.
The current study analysed data from the Finnish Can-
cer Registry (FCR) to determine the incidence of EPC in 
Finland during 2007 to 2017. As a secondary aim, this 
study also estimated the survival of patients with EPC.
PATIENTS AND METHODS
The institutional ethics committee of Helsinki University Hospital 
approved the study (HUS/358/2018). After consulting the data 
protection authority, the Finnish Institute of Health and Welfare 
granted permission to use the registry information on patients with 
EPC from the FCR in scientific research. 
The FCR was founded in 1952 and maintains a nationwide 
population-based database of all cancer cases in Finland. Its 
coverage is virtually complete, as evidenced by clinical studies 
on national cancer incidence and treatment results (12). All 
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physicians, hospitals and pathology and haematology laboratories 
in Finland are obliged to submit data on cancer patients to the FCR.
The FCR coding system was updated in 2007, from the 7th ver-
sion of the International Classification of Diseases (ICD-7) to the 
International Classification of Diseases for Oncology, version 3 
(ICD-O-3). Before 2007 there was no morphology code for EPC, 
and it was not possible to separate EPC as a separate disease entity. 
Therefore, this study focused on persons diagnosed during 2007 
to 2017 with EPC (ICD-O-3 morphology code M8409/3).
Incidence rates per 100,000 person-years were calculated by 
sex and 5-year age groups, using population counts from Statistics 
Finland. The incidence rates were age-standardized to the World 
Standard Population (WSP) version 1966 (13). To compare these 
results with previous studies age-standardized incidence rates 
were also calculated, using the European Standard Population 
(ESP) (14).
For survival analyses, follow-up started from the date of diag-
nosis and ended at the date of death, emigration, or date of close 
of the study (31 December 2017), whichever occurred first.
RESULTS
From 2007 to 2017 there were 69 cases of EPC recorded 
in the FCR. In all cases the diagnosis was confirmed 
by histology from the primary tumour. There were 34 
(49%) male and 35 (51%) female patients and mean 
age at diagnosis was 75.5 years. Using the WSP, the 
age-adjusted incidence per 100,000 person-years was 
0.06 for men and 0.04 for women, and, using the ESP, 
0.15 and 0.10, respectively. The incidence rate was 
relatively consistent during the study period, except 
for the year 2016 (Table I). Incidence started increa-
sing strongly after the age of 70 years (Fig. 1). In men 
incidence showed a small rise at a slightly earlier age 
than in women.
The most common location of EPC was on the lower 
limb, including the hip (20 cases; 29%) followed by 
unspecified parts of the face (16 cases; 23%) and the 
trunk, including the genitalia (12 cases; 17%). Other 
locations were the scalp and neck (9 cases; 13%), upper 
limb including the shoulder (7 cases; 10%), unspecified 
skin (3 cases; 4%), and in the ear and external auricular 
canal (2 cases; 3%). Taken together, all head and neck 
locations accounted for 39% of cases.
EPC was the first primary cancer in 42 of patients 
(61%) when basal cell carcinoma was included, and in 
47 of patients (68%) when basal cell carcinoma was ex-
cluded. In one patient EPC and squamous cell carcinoma 
were diagnosed at the same time.
Survival of patients with EPC was similar to the ge-
neral population of similar age (relative 5-year survival 
rate 104%). One EPC-specific death was recorded during 
the study period.
DISCUSSION
This study provides incidence estimates with a national 
coverage of the rare skin cancer EPC. There were ap-
proximately 7 cases of EPC annually between 2007 and 
2017 in the Finnish population of 5.6 million. The mean 
age was consistent with previous studies; 75.5 years at 
presentation, respectively (4, 9). The age-adjusted inci-
dence rate per 100,000 person-years was 0.06 for men 
and 0.04 for women when using WSP, and 0.15 for men 
and 0.10 for women using ESP. The locations of the 
primary tumour were consistent with previous reports (4, 
9, 10); the head and neck region and lower limbs were 
the most common locations, as was observed in nearly 
40% and 29%, respectively, of cases in the current study. 
The largest series of EPC has been described by 
Robson et al. (2) (69 cases) and Goon et al. (15) (153 
cases). Incidence rates of EPC have been rarely reported. 
A widely cited number is “0.01% of all skin cancers”, 
which refers to the study by Mehregan et al. (16). This 
number is derived from approximately one case of EPC 
per 13,000 specimens received in a dermatopathology 
laboratory. EPC represented 7% of the skin adnexal 
tumours in the Netherlands, and the age-standardized 
rate using the ESP for males in 1989–2010 was 0.04 
and for females 0.03 per 100,000 person-years, i.e. ap-
proximately one-third of the rates observed in the current 
study (6). The age-standardized rates (ESP) from 2004 
Table I. Number of cases with age-standardized (World Standard 
Population) incidence rates of malignant eccrine porocarcinoma 
(EPC) per 100,000 person-years in Finland
Year Cases, n
























Fig. 1. Incidence of malignant eccrine porocarcinoma per 100,000 
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to 2013 from East England (males 2.4, females 1.3 per 
100,000 person-years) were at least 10 times higher than 
our rates (15). In Minnesota, the incidence rates for both 
females and males were 0.2 per 100,000 person-years 
(17). They adjusted their rates to the US population from 
2010, which is not very different from the ESP, and it 
can therefore be concluded that the incidence of EPC is 
only slightly higher than the rate in Finland. We stron-
gly believe that the incidence rates found in the current 
study are true estimates of the numbers of cancer cases 
diagnosed as EPC in Finland, and that the number of 
EPCs misdiagnosed as other cutaneous cancers is small. 
Based on this information, it does not seem possible that 
the rates published from East England are correct. The 
rates predicted for year 2030 (15) would mean that the 
incidence of EPC would be approximately 30-fold that of 
the current rate in Finland or in Minnesota, and 100-fold 
that from a study in the Netherlands (6). 
In contrast to earlier publications, EPC-specific mor-
tality in the current series was very low, with only one 
death in 11 years. The survival of patients with EPC is 
therefore no worse than that of other Finns of similar 
age (5-year relative survival rate 104%). In the previous 
literature, at the time of diagnosis up to 30% of patients 
had metastases (4, 9), mostly in the regional lymph nodes. 
During follow-up of the EPCs, up to 25% progressed to 
regional metastases and 12% to distant metastases (1–3, 
15). However, only 7–13% of patients died due to EPC 
(3, 16). In more recent reports, the aggressiveness of EPC 
was questioned, and the results suggest that aggressive 
behaviour and metastases may be an exception in EPC 
(3, 10, 18). The results of the current study are in line 
with the newer data; only one of the 69 patients with 
EPC died from EPC during the mean follow-up period 
of approximately 5 years.
This study found a relatively stable annual incidence 
of EPC, except for the year 2016, when it was much 
higher. However, in a rare cancer such as EPC, the pos-
sibility of chance cannot be excluded. Another Finnish 
study of a different rare skin cancer, Merkel cell car-
cinoma, observed that even one article or presentation 
at a congress may increase clinician’s knowledge and 
sensitivity to a rare skin cancer diagnosis and lead to a 
peak in incidence (19). The histological diagnosis of EPC 
is difficult. Diagnosis should be based on the presence of 
at least atypical poroid cells and ductal formation with 
typical histology. EPC has no specific immune-profile. 
EPC expresses carcinoembryonic antigen and epithelial 
membrane antigen, but so does benign poroma (2–4). 
Expression of CD117 can be used to differentiate EPC 
from squamous cell carcinoma, whereas S-100 can be 
used especially in diagnosis of dedifferentiated EPC and 
is expressed only in dendritic cells within the tumour 
(2, 13, 20–22). EPC may be erroneously diagnosed as 
squamous cell carcinoma and vice versa; however, the 
presence of neoplastic ducts is necessary for a diagnosis 
of EPC. Currently no immunostaining has been shown 
to have superiority for EPC diagnosis. As the data on 
EPC are accumulating, it is possible that a diagnostic 
immunostaining profile will be established.
Given the quality of the national cancer registry in 
Finland (12), the incidence estimates presented in this 
paper probably include most, if not all, diagnosed cases 
of EPC that occurred in Finland over the study period. 
However, it must be noted that this study cannot address 
the possibility of underdiagnosis of EPC. In particular, 
poorly differentiated EPC can easily be misdiagnosed as 
other skin carcinomas. The FCR gets information from 
pathology reports from all laboratories and, if there is 
conflicting information, selects the diagnosis considered 
most reliable. In earlier years FCR sometimes asked for 
pathological slides for re-evaluation by a panel of patho-
logists. The outcome of such quality control operations 
was that the quality of the pathological diagnoses per-
formed in Finnish hospitals is good. In the case of EPC, 
it is possible that pathologists may have not been aware 
of this diagnosis option and therefore the number of 
cases of EPC is a minimum estimate of the true number.
In conclusion, this study confirms the low incidence of 
EPC in Finland. In line with recent studies, these results 
suggest very low mortality due to EPC. However, the ra-
rity of EPC poses limitations on the interpretation of these 
results. This study was based solely on cancer registry 
data; further studies with clinical insight are warranted. 
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